Durvalumab
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Unresectable Non-small Cell Lung Cancer (NSCLC)
Conditions
Unresectable Non-small Cell Lung Cancer (NSCLC)
Trial Timeline
Nov 30, 2021 → Oct 27, 2023
NCT ID
NCT04416633About Durvalumab
Durvalumab is a approved stage product being developed by AstraZeneca for Unresectable Non-small Cell Lung Cancer (NSCLC). The current trial status is completed. This product is registered under clinical trial identifier NCT04416633. Target conditions include Unresectable Non-small Cell Lung Cancer (NSCLC).
What happened to similar drugs?
0 of 20 similar drugs in Unresectable Non-small Cell Lung Cancer (NSCLC) were approved
Approved (0) Terminated (1) Active (19)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06992609 | Phase 3 | Recruiting |
| NCT06826677 | Pre-clinical | Completed |
| NCT05925530 | Phase 2 | Active |
| NCT04944173 | Phase 2 | Withdrawn |
| NCT05924880 | Phase 3 | Completed |
| NCT05617963 | Phase 2 | Recruiting |
| NCT05683977 | Pre-clinical | Active |
| NCT05303532 | Phase 3 | Recruiting |
| NCT05215106 | Phase 2 | Recruiting |
| NCT04416633 | Approved | Completed |
| NCT05933044 | Pre-clinical | Completed |
| NCT04765709 | Phase 2 | Terminated |
| NCT04667312 | Pre-clinical | Completed |
| NCT04062708 | Phase 2 | Active |
| NCT04230408 | Phase 2 | Completed |
| NCT04441138 | Phase 2 | Terminated |
| NCT05267392 | Phase 1/2 | UNKNOWN |
| NCT04543110 | Phase 2 | UNKNOWN |
| NCT04716946 | Phase 2 | Active |
| NCT04642469 | Phase 3 | Completed |
Competing Products
20 competing products in Unresectable Non-small Cell Lung Cancer (NSCLC)